Adrian Woolfson Email & Phone Number

I am the Founder of Replay, a private equity and VC-funded gene and cell therapy company headquartered in San Diego, California. Replay is progressing an HSV-based gene therapy into the clinic. I was formerly Executive Chairman, and President of Replay. Prior to that I was EVP and Head of R&D at SGMO, leading programs in gene editing, in vivo genome engineering, transcriptional repression, gene therapy, autologous CAR-Treg, and allogeneic CAR-T cell therapy. Prior to that I was CMO of the 5AM-, LSP-, Abingworth-, and Versant-backed cancer neoantigen vaccine and oncolytic virus company Nouscom, based in Basel, Switzerland, and Rome, Italy. I was Global Clinical Leader of Early and Late Stage Immuno-Oncology/Hematology at Pfizer based in New York, and held positions of increasing responsibility at Bristol-Myers Squibb in London UK and Princeton, New Jersey. My graduate and post-graduate medical training was in London, Oxford, and Cambridge, UK. I was awarded the Jelf Medal, the highest honor that King’s College can bestow on its students. My PhD and post-doctoral work on molecular immunology was supervised by Nobel Prize winner, inventor of monoclonal antibodies, and discoverer of CD antigens, César Milstein. I was the Charles and Katharine Darwin Research Fellow at Darwin College Cambridge, UK, a Welcome Trust Clinical Research Fellow, and a National Foundation for Cancer Research Fellow at the MRC Laboratory of Molecular Biology in Cambridge, UK, where I worked on alternative splicing and protein folding. I have authored over 150 publications, including two critically acclaimed books, book chapters, reviews, and peer-reviewed scientific papers. I have authored several patents addressing I-O therapy, synthetic DNA assembly, immune silencing, synthetic protein refolding machinery, and barcoding of human diseases using machine learning and soluble immune proteins. I am a regular contributor to The Wall Street Journal, The Washington Post, and Science magazine, and contribute to various other publications including: Nature, The Spectator, The New Statesman, Financial Times, Prospect, The Times Literary Supplement, and The Literary Review. I am a Co-founder, Editorial Board member, and Books Review Editor of the GEN Biotechnology journal. I am on the Board of Directors of the Singapore- and San Diego-based TCR-T cell therapy company ImmunoScape. My new book, ‘The Future of Species’ will be published by Bloomsbury on 26 February 2026.

Listed skills include Oncology, Drug Development, Biotechnology, Cancer, and 10 others.